financetom
Business
financetom
/
Business
/
Kits Eyecare Q3 Earnings Miss Expectations, But Revs Beat; Also Flags Revs Beat In Q4
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kits Eyecare Q3 Earnings Miss Expectations, But Revs Beat; Also Flags Revs Beat In Q4
Nov 6, 2024 6:12 AM

08:34 AM EST, 11/06/2024 (MT Newswires) -- Kits Eyecare ( KTYCF ) reported Wednesday a slight earnings miss for the third quarter, even as revenues beat expectations, and the company flagged higher than expected revenues for the fourth quarter.

The company recorded third quarter net earnings of $0.132 million, or $0.00 per share, down from near $0.5 million, or $0.02 basic and $0.01 diluted a year earlier. It missed a consensus mean of $0.01 EPS GAAP at Capital IQ.

Revenue for the quarter ended Sept. 30 was $41.9 million, up 34.3% from $31.2 million a year earlier; analysts surveyed by Capital IQ had projected $41.7 million.

For the fourth quarter, Kits Eyecare ( KTYCF ) expects revenue between $43 million and $45 million, with adjusted EBITDA margins anticipated to be between 3% and 5%. The consensus forecast for Q4 at Capital IQ was $40.60 million.

Kits Eyecare ( KTYCF ) shares closed at $10 on Monday, up 0.20%.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Aprea Therapeutics' Q3 net loss narrows
Aprea Therapeutics' Q3 net loss narrows
Nov 12, 2025
Overview * Aprea Q3 net loss narrows to $3.0 mln from $3.8 mln in prior yr * Company's cash position expected to support operations into Q4 2026 * Clinical progress in WEE1 and ATR inhibitor programs noted Outlook * Aprea plans to explore combination strategies for ATRN-119 with radiation or checkpoint inhibitors * Company progressing with dose escalation for APR-1051...
Indaptus Therapeutics Q3 profit beats estimates
Indaptus Therapeutics Q3 profit beats estimates
Nov 12, 2025
Overview * Indaptus Q3 2025 EPS beats analyst expectations, improving from last year's loss * Company raised $2.3 mln through at-the-market facility, strengthening balance sheet * Research and development expenses increased due to Phase 1 study costs Outlook * Indaptus expects current cash to support operations into Q1 2026 * Company is evaluating financing options to support its strategy *...
Fortune Bay Advancing Goldfields Project Development Toward PFS
Fortune Bay Advancing Goldfields Project Development Toward PFS
Nov 12, 2025
08:38 AM EST, 11/12/2025 (MT Newswires) -- Fortune Bay ( FTBYF ) said Wednesday that it has initiated key technical work streams to advance the Goldfields Project in Saskatchewan toward a pre-feasibility study (PFS) next year. A drilling program for the Box and Athona deposits in Goldfields is being planned, to provide the required drill coverage and core samples to...
Immatics Says Two Product Candidates Show Favorable Tolerability in Patients With Solid Tumors
Immatics Says Two Product Candidates Show Favorable Tolerability in Patients With Solid Tumors
Nov 12, 2025
08:32 AM EST, 11/12/2025 (MT Newswires) -- Immatics ( IMTX ) said Wednesday that updated phase 1a dose escalation data from the two product candidates in its TCR Bispecifics pipeline showed favorable tolerability at the recommended phase 2 dose in patients with advanced metastatic solid tumors. The IMA402 and IMA401 TCR Bispecifics also demonstrated deep and durable responses in heavily...
Copyright 2023-2026 - www.financetom.com All Rights Reserved